Jie Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jie Zhang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Liang Cai
State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau (SAR), China
2 shared publicationsChongfan Zhang
Fudan University GRADE Center, Children's Hospital of Fudan University, 210102, China
1 shared publicationDan Wang
Xiamen Ginposome Pharmaceutical Co., Ltd. Xiamen, FuJian, China
1 shared publicationFuqiang Shao
Department of Nuclear Medicine, Zigong First People's Hospital, Zigong, Sichuan, PR China
1 shared publicationHai-Bin Luo
School of Pharmaceutical Science, Sun Yat-sen University, China
1 shared publicationHuan-Xing Zhan
Xiamen Ginposome Pharmaceutical Co., Ltd. Xiamen, FuJian, China
1 shared publication
Latest Publications
- 15 February 2023
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 72, 104571
Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease
- 15 February 2023
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 72, 104571
Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease
- 12 April 2020
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 146 (6) , 1533-1543
The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
Purpose To evaluate the efficacy of 177Lu-DOTA0-Tyr3-octreotate (177Lu-DOTATATE) radionuclide therapy in patients with inoperable or metastatic neuroendocrine tumours (NETs), (PROSPERO ID CRD42019130755). Methods All published clinical studies of NETs treated with 177Lu-DOTATATE were identified based on systematic searches in the PubMed, EMBASE, Cochrane Library, Web of Science and ClinicalTrials.gov databases up to January 2019. Among these studies, only the reports evaluated with the “Response Evaluation Criteria in Solid Tumours (RECIST)” or “Southwest Oncology Group (SWOG)” criteria or both were included. We analysed the disease response rate (DRR) and disease control rate (DCR) of each group to evaluate the efficacy of 177Lu-DOTATATE. Results Fifteen studies were selected from 715 references. The pooled effect in the RECIST group (13 studies) was 27.58% (95% confidence interval (CI) 21.03–35.27%) for the DRR and 79.14% (95% CI 75.83–82.1%) for the DCR. In the SWOG criteria group (7 studies), the pooled effect was 20.59% (95% CI 10.89–35.51%) for the DRR and 78.28% (95% CI 74.39–81.72%) for the DCR. Therefore, the RECIST and SWOG groups showed similar DRRs and DCRs after177Lu-DOTATATE treatment, indicating that 177Lu-DOTATATE treatment has excellent efficacy with a control rate of approximately 78–79%. Moreover, adverse effects of 177Lu-DOTATATE were minimal, including fatigue, nausea, vomiting and hormonal disorders. Conclusions For patients with inoperable or metastatic NETs, 177Lu-DOTATATE is an effective treatment with minimal side effects.
- 12 April 2020
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 146 (6) , 1533-1543
The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
Purpose To evaluate the efficacy of 177Lu-DOTA0-Tyr3-octreotate (177Lu-DOTATATE) radionuclide therapy in patients with inoperable or metastatic neuroendocrine tumours (NETs), (PROSPERO ID CRD42019130755). Methods All published clinical studies of NETs treated with 177Lu-DOTATATE were identified based on systematic searches in the PubMed, EMBASE, Cochrane Library, Web of Science and ClinicalTrials.gov databases up to January 2019. Among these studies, only the reports evaluated with the “Response Evaluation Criteria in Solid Tumours (RECIST)” or “Southwest Oncology Group (SWOG)” criteria or both were included. We analysed the disease response rate (DRR) and disease control rate (DCR) of each group to evaluate the efficacy of 177Lu-DOTATATE. Results Fifteen studies were selected from 715 references. The pooled effect in the RECIST group (13 studies) was 27.58% (95% confidence interval (CI) 21.03–35.27%) for the DRR and 79.14% (95% CI 75.83–82.1%) for the DCR. In the SWOG criteria group (7 studies), the pooled effect was 20.59% (95% CI 10.89–35.51%) for the DRR and 78.28% (95% CI 74.39–81.72%) for the DCR. Therefore, the RECIST and SWOG groups showed similar DRRs and DCRs after177Lu-DOTATATE treatment, indicating that 177Lu-DOTATATE treatment has excellent efficacy with a control rate of approximately 78–79%. Moreover, adverse effects of 177Lu-DOTATATE were minimal, including fatigue, nausea, vomiting and hormonal disorders. Conclusions For patients with inoperable or metastatic NETs, 177Lu-DOTATATE is an effective treatment with minimal side effects.
- Open Access
- 1 March 2020
- Published by Elsevier in Journal of Ginseng Research
- Vol. 44 (2) , 247-257
Ginsenoside Rg5 overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter: in vitro and in vivo study
- 1 March 2020
- Published by Elsevier in Journal of Ginseng Research
- Vol. 44 (2) , 247-257
Open AccessGinsenoside Rg5 overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter: in vitro and in vivo study
- 1 March 2019
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 44 (3) , 262-264
Diffuse Intense Intestinal FDG Activity in a Patient With Familial Adenomatous Polyposis
Familial adenomatous polyposis is a rare autosomal dominant intestinal syndrome with a high rate of malignant transformation. Here, we report a 20-year-old woman with a diagnosis of familial adenomatous polyposis by pathologic examination after colonoscopy biopsy, who underwent an 18F-FDG PET/CT to assess the extent of this disease. The images showed diffuse elevated FDG uptake along the entire colorectum. Additionally, focal enlarged lymph nodes with increased FDG uptake were noted. These findings promoted proctocolectomy and lymphadenectomy.
- 1 March 2019
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 44 (3) , 262-264
Diffuse Intense Intestinal FDG Activity in a Patient With Familial Adenomatous Polyposis
Familial adenomatous polyposis is a rare autosomal dominant intestinal syndrome with a high rate of malignant transformation. Here, we report a 20-year-old woman with a diagnosis of familial adenomatous polyposis by pathologic examination after colonoscopy biopsy, who underwent an 18F-FDG PET/CT to assess the extent of this disease. The images showed diffuse elevated FDG uptake along the entire colorectum. Additionally, focal enlarged lymph nodes with increased FDG uptake were noted. These findings promoted proctocolectomy and lymphadenectomy.